FDA approves Roche ’s Actemra/RoActemra (tocilizumab) for giant cell arteritis

Roche today announced that the U.S. Food and Drug Administration (FDA) has approved Actemra ®/RoActemra® (tocilizumab) ) subcutaneous injection for the treatment of GCA, a chronic and severe autoimmune condition.
Source: Roche Investor Update - Category: Pharmaceuticals Source Type: news